The MarketWatch News Department was not involved in the creation of this content. HINGHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of ...

HINGHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer and distributer of the innovative LIBERTY ® Endovascular Robotic System, today announced that it will be ...

HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY ® Endovascular Robotic System, announces that its Chief ...

HINGHAM, MA – Microbot Medical Inc. (NASDAQ:MBOT), a clinical-stage medical device company with a market capitalization of $43.2 million, announced significant developments, including fundraising ...

HINGHAM, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced it has been approved to receive a ...

BRAINTREE, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced its agreement with Brigham and Women’s Hospital (BWH), a leading academic medical center located in ...

Microbot shares are trading higher Monday after the company received FDA approval to proceed with its human clinical trial. Microbot says the study will be conducted in the U.S., and it has already ...

Microbot Medical Inc. MBOT recently announced the successful completion of its GLP pivotal pre-clinical study. The study was conducted under the guidelines of the FDA-required levels of planning, ...

HINGHAM, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, is continuing to generate ...

First U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System Company Completes the Recruitment of its ...